HIBOR\u00ae is the commercial brand name of Bemiparin Sodium Injection, developed and manufactured by Laboratorios Farmac\u00e9uticos ROVI, S.A. It belongs to low molecular weight heparin. It exerts anti-Xa and weak anti-IIa effects to suppress platelet aggregation and coagulation factor activity, achieving stable anticoagulation through subcutaneous administration with low bleeding risk.<\/p>\n\n\n\n
Main Indications<\/strong> Clinical Research<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy HIBOR (Bemiparin Sodium Injection)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" HIBOR\u00ae is the commercial brand name of Bemiparin Sodium Injection, developed and manufactured by Laboratorios Farmac\u00e9uticos ROVI, S.A. It belongs to low molecular weight heparin. It exerts anti-Xa and weak anti-IIa effects to suppress platelet aggregation and coagulation factor activity, achieving stable anticoagulation through subcutaneous administration with low bleeding risk. Main IndicationsProphylaxis of venous thromboembolism […]<\/p>\n","protected":false},"author":4,"featured_media":4442,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-4441","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Prophylaxis of venous thromboembolism in surgical patients and bedridden medical patients;
Treatment of established deep vein thrombosis with or without pulmonary embolism;
Anticoagulation during hemodialysis.<\/p>\n\n\n\n
Multicenter global clinical trials verified its anticoagulation efficacy and safety. Thromboembolism prevention trials proved it effectively reduces the incidence of postoperative venous thrombosis with convenient once-daily dosing. Therapeutic anticoagulation trials showed non-inferior efficacy against standard low molecular weight heparins for deep vein thrombosis treatment. Hemodialysis observational studies demonstrated stable anticoagulant performance during extracorporeal circulation. Tolerability research reflected mild local injection reactions as the main mild adverse event, with low overall bleeding incidence. Long-term prophylaxis trials confirmed sustained reliable safety profile for prolonged preventive use.<\/p>\n\n\n\n
Common mild adverse reactions: Local injection site bruising, mild pain, slight thrombocytopenia and transient elevated liver enzymes;
Laboratory abnormalities: Transient mild increase in liver transaminases;
Severe but uncommon risks: Severe hemorrhage, heparin-induced thrombocytopenia, hypersensitivity and skin necrosis at injection site.<\/p>\n\n\n\n
HIBOR\u00ae (specification 0.2ml:3500 IU anti-Xa, 10 pre-filled syringes per box) obtained marketing approval in China in 2019. It is a subcutaneous injectable prescription anticoagulant drug covered by China\u2019s Category B medical insurance catalogue.<\/p>\n\n\n\n